Search Results - kristen+kokkonen

2 Results

Sort By:

New Method of mTOR Regulation by TSC2 Modification

Unmet NeedImmunotherapies that boost T cell responses have demonstrated therapeutic efficacy in numerous cancers. To improve the efficacy and expand the clinical utility of immunotherapy, improved methods of stimulating T cell responses are needed. mTORC1 is a critical regulator of T cell activation, differentiation and function. While modulating mTORC1...

Published: 3/13/2025 | Inventor(s): David Kass, Mark Ranek, Kristen Kokkonen, Jonathan Powell, Chirag Patel

Keywords(s): Cancers, Cell Therapy/Gene Therapy, Combination, Disease Indication, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities

Targeting TSC2 S1366 (mouse, rat) S1365 (human) by gene engineering or phosphorylation to Regulate mTOR Signaling Cascades for Therapeutic Indications

Unmet NeedThe mechanistic target of rapamycin complex-1 (mTORC1) coordinates cellular processes and regulates recycling pathways in order to control cell growth and metabolic homeostasis. Additionally, in immune cells when the T-cell receptor is activated, the mTORC1 signaling pathway is also engaged and thus plays an important role in T-cell activation,...

Published: 3/14/2025 | Inventor(s): David Kass, Kristen Kokkonen, Brittany Dunkerly-Eyring, Mark Ranek

Keywords(s): Disease Indication, Inflammatory Disorders, Target, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Targets